---
figid: PMC4858579__tlcr-05-02-172-f3
figtitle: Inhibition of EMT in NSCLC cells
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4858579
filename: tlcr-05-02-172-f3.jpg
figlink: /pmc/articles/PMC4858579/figure/f3/
number: F3
caption: Inhibition of EMT in NSCLC cells. (A) The HDAC inhibitor entinostat maintains
  an open chromatin structure and the transcription of E-cadherin. Entinostat hereby
  enforces the epithelial state and prevent EMT; (B) selumetinib inhibits MEK and
  thus the MAPK pathways. As the MAPK pathway is involved in receptor tyrosine kinase
  signaling as well as TGF-β signaling, selumetinib has potential both as a first
  line treatment and as a treatment upon resistance development. EMT, epithelial to
  mesenchymal transition; NSCLC, non-small cell lung cancer; HDAC, histone deacetylase;
  TGF-β, transforming growth factor-β.
papertitle: The role of epithelial to mesenchymal transition in resistance to epidermal
  growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
reftext: Kristine Raaby Jakobsen, et al. Transl Lung Cancer Res. 2016 Apr;5(2):172-182.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9511473
figid_alias: PMC4858579__F3
figtype: Figure
redirect_from: /figures/PMC4858579__F3
ndex: 6d373105-de8d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4858579__tlcr-05-02-172-f3.html
  '@type': Dataset
  description: Inhibition of EMT in NSCLC cells. (A) The HDAC inhibitor entinostat
    maintains an open chromatin structure and the transcription of E-cadherin. Entinostat
    hereby enforces the epithelial state and prevent EMT; (B) selumetinib inhibits
    MEK and thus the MAPK pathways. As the MAPK pathway is involved in receptor tyrosine
    kinase signaling as well as TGF-β signaling, selumetinib has potential both as
    a first line treatment and as a treatment upon resistance development. EMT, epithelial
    to mesenchymal transition; NSCLC, non-small cell lung cancer; HDAC, histone deacetylase;
    TGF-β, transforming growth factor-β.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Tie
  - Ras85D
  - InR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Pdk1
  - Raf
  - Dsor1
  - Mtk
  - Akt
  - Erk7
  - rl
  - tor
  - Tor
  - HDAC4
  - HDAC6
  - HDAC1
  - HDAC3
  - ac
  - shg
  - EGFR
  - TGFBR1
  - TGFBR2
  - TGFBR3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - PDK1
  - PDPK1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - RORC
  - HDAC9
  - HDAC2
  - HDAC8
  - HDAC5
  - HDAC7
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - ACACA
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - ITK
  - SLC22A3
  - CDH1
  - Selumetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
